1429 - Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)

Primary Author / Presenter(s)

Huayuan Zhu, MD

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)

Co-Author(s)

YM

Yi Miao, MD

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
ML

Ming Liu

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
Shuchao Qin, PhD

Physician
Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital
Nanjing, Jiangsu, China (People's Republic)
Fl

Fei li, PhD

The First Affiliated Hospital of Nanchang University
Jiangxi Province Nanchang City, Jiangxi, China (People's Republic)
JZ

Jin Zhang

Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China (People's Republic)
HP

Hongling Peng, Dr

The Second Xiangya Hospital of Central South University
Changsha, China (People's Republic)
CJ

Chunyan Ji, Professor

Qilu Hospital, Cheeloo College of Medicine, Shandong University, Hematology Department, Jinan, China, Shandong, China (People's Republic)
LD

Luomengjia Dai, MD

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
ZZ

Ziyuan Zhou, MD

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
CD

Chongyang Ding

the First Affiliated Hospital of Nanjing Medical University
Nanjing, China (People's Republic)
ZW

Zhen Wang, MD, PhD

Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University
Nanjing, China (People's Republic)
Yeqin Sha, MD

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
TQ

Tong-lu Qiu, MD

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
HT

Hanning Tang

the First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
HJ

Hui Jin, MD

Research fellow
the First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
Lei Fan, MD

the First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)
Wei Xu, MD

1. Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjing, Jiangsu, China (People's Republic)
JL

Jianyong Li, MD

Chief of Hematology department
Department of Hematology, Key Laboratory of Nanjing Medical University, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China
Nanjing, Jiangsu, China (People's Republic)
Yi Xia, MD

Attending Physician, Department of Hematology
Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, Jiangsu, China (People's Republic)